Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Ocusoft Inc. maintains a patent portfolio focused on Biotechnology & Pharmaceuticals, currently navigating 4 pending office actions. These actions are distributed across 3 distinct art units, indicating that the company's intellectual property strategy involves diverse technical sub-specialties within the biotechnology sector. The prosecution workload is spread among the same number of distinct examiners, ensuring that no single individual's review style dominates the entire portfolio's progress.
The busiest examiner for the company is THOMAE, EVAN GODFREY, who is responsible for 1 pending action. This distribution shows that the pending office actions are handled by different examiners, as the busiest examiner's count is limited to 1. Such a spread suggests a lack of examiner-specific bottlenecks, as the workload is broadly distributed across the available examiners.
Practitioners should note that the presence of 3 distinct art units requires familiarity with multiple sets of examination guidelines or technical standards. The relationship between the number of actions and examiners highlights a diversified prosecution landscape where each matter receives independent review within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| THOMAE, EVAN GODFREY | 1 | — | — |
| SPAINE, ROBERT FRANKLIN | 1 | 75.0% | +0.0% |
| YU, HONG | 1 | 30.9% | +5.6% |
| EKRAMI, YASAMIN | 1 | 41.6% | +46.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17861588 | SKIN MOISTURIZING COMPOSITIONS | YU, HONG | 16d overdue |
| 18639128 | ANTI-ALLERGENIC OCULAR COMPOSITIONS | SPAINE, ROBERT FRANKLIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16683660 | EYE MASK | EKRAMI, YASAMIN | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1614 | 1 |
| 3794 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19069015 | TOPICAL FORMULATIONS FOR THERAPEUTICALLY ACTIVE AGENTS | THOMAE, EVAN GODFREY | — | §103 | Non-Final OA | — | Pending | Mar 03, 2025 |
| 18639128 | ANTI-ALLERGENIC OCULAR COMPOSITIONS | SPAINE, ROBERT FRANKLIN | 1655 | §101§103§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 17861588 | SKIN MOISTURIZING COMPOSITIONS | YU, HONG | 1614 | §102§103 | Non-Final OA | 16d overdue | Pending | Jul 11, 2022 |
| 16683660 | EYE MASK | EKRAMI, YASAMIN | 3794 | §103 | Non-Final OA | — | Pending | Nov 14, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial